Xarelto Defendants: Third Time Lucky
Xarelto Defendants: Third Time Lucky
Introduction
The third straight win for Xarelto defendants in the Xarelto MDL No. 2592 bellwether trial, boosts the defendant's stand regarding the safety and efficacy of Xarelto. Bayer released a statement saying, ''that its FDA-approved label contains accurate, science-based information on the benefits and risks of this life-saving medicine.” This decision came in by the Mississippi federal jury in favor of the defendants: J&J's Janssen Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals Inc. The plaintiff alleged that the Prothrombin Time (PT) test which is used to assess a patient's risks for bleeding, was not informed and instructed to the doctors by the manufacturers. This was opposed by the defendant's say that the PT test was not scientifically reliable.
Comments
Latest News
Spokane County to Get $5M in New Opioid Settlement
Categories: Opioids
Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.
The agreement addresses the company’s role in fueling…
Purdue, Sacklers Agree to New $7.4B Opioid Settlement
Categories: Opioids
All 50 U.S. states, along with the District of Columbia and U.S. territories, have agreed to a $7.4 billion settlement with Purdue Pharma, the manufacturer of OxyContin.
This deal addresses allegations that the company’s aggressive and…
Oregon to Get $66M in Sackler Opioid Settlement
Categories: Opioids
Oregon will gain $66 million as part of a nationwide settlement with the Sackler family and Purdue Pharma, the makers of OxyContin. The funds will be used to expand and…